Differences in Influence between Intravenous Methylprednisolone and Intramuscular Progesterone toward Erectile Function After Operation Transurethral Resection of the Prostate (TUR-P) in Patients Benign Prostate Hyperplasia (BPH)

Authors

  • Monica Yolanda Masters Program in Family Medicine, Sebelas Maret University, Jl. Ir. Sutami 36 A, Surakarta 57126, Central Java
  • Setya Anton Tusarah Masters Program in Family Medicine, Sebelas Maret University
  • Untung Alifianto Masters Program in Family Medicine, Sebelas Maret University

Abstract

Background: Erectile function is an important factor for all men in an active sexual condition, as well as to assess the quality of sex life with their partners. Transurethral Resection of the Prostate (TURP) is a gold standard action for Benign Prostate Hyperplasia (BPH). The researcher tried to study to investigate the effect of corticosteroid and progesterone on erectile function in BPH patients who have done TURP surgery by using Erection Hardness Score (EHS). The purpose of this study was to investigate the effect of intra venous methylprednisolone on post-operative erection function of TURP in BPH patients. To investigate the effect of intra-muscular progesterone on postoperative erectile function of TURP in BPH patients. To investigate the different effect between methylprednisolone and progesterone on post-operative erection function of TURP in BPH patients.

Subjects and Method: Subjects of all BPH patients who performed TUR-P surgery in the urology sub-section of Dr. Moewardi Hospital, Surakarta. The sampling technique in this study was incidental sampling. This study was a clinical experimental study using Pre and Post-test design-Only Control Design. 3 groups were divided to get different treatment, the first group was given methylprednisolone, the second group was given progesterone and the third group was given TURP therapy protocol only.

Results: After 1 month of TURP treatment in BPH patients, the result obtained for the EHS which on a scale of 2 and 3. EHS on scale 2 for the methylprednisolone group was 9 patients (69.2%), the progesterone group had 6 patients (46.2%), and the control group had 8 of patients (66.7%). Meanwhile, EHS on scale 3 for the methylprednisolone group was 4 patients (30.8%), there were 7 patients (53.8%) of the progesterone group, and the control group had 4 patients (33.3%). After 3 months of TURP treatment in BPH patients, EHS on scale 2 in the methylprednisolone group there were 2 patients (15.4%), the progesterone group there were 0 patients (0.0%), and the control group there were 6 patients (50.0%). The methylprednisolone group had 9 patients (69.2%) on EHS 3 scale, the progesterone group had 4 patients (30.8%), and there were 6 patients (50.0%) in the control group. While, EHS scale of 4 the total of the patients in the methylprednisolone group was 2 patients (15.4%), the progesterone group had 9 patients (69.2%), and the control group had 0 patients (0.0%).

Conclusion: the methylprednisolone improved the erectile function in post-operative TURP patients. Progesterone improved erectile function in post-operative TURP patients. Therefore, it can be concluded that progesterone was better than methylprednisolone. 

Keywords: Erectile dysfunction, Methylprednisolone, Progesterone

Correspondence: Monica Yolanda. Masters Program in Family Medicine, Sebelas Maret University, Jl. Ir. Sutami 36 A, Surakarta 57126, Central Java. Email: monica_mail83@yahoo.co.id.

Indonesian Journal of Medicine (2017), 2(2): 116-124
https://doi.org/10.26911/theijmed.2017.02.02.06

 

References

Akbal C, Turker R, Tavukeu H (2007). Erectile function in Benign prostate hyperplasia – patients who underwent transuretrhral resection, European Urology, 53: 540-46.

Anjum I, Ahmad M, Azzopardi A, Mutfi GR (1998). Prostatic infection in acute urinary retention secondary to benign prostate hyperplasia. American Journal of Urology, 160: 792-3.

Berardis GD, Francoisi M, Belfiglio M, Dinardo B, Kaplan SH (2002). Erectile dysfunction and quality of life in type 2 diabetics patients. Diabetic Care, 25: 284-91.

Boyle P, Liu GF (2001). Epidemiology and Natural History. In the: Chatelain, Denis L, eds. Benign Prostat Hyperplasia, 5th United Kingdom: Plymbrige, 19-61.

Brosman SA (2009). Prostate Specific Antigen. Diambil dari: http://www.emedicine.com./articles.

Choi SB, Zhao C, Park JK (2010). The Effect of Transuretrhal Resection of the Prostate on Erectile Function in Patients with Benign Prostate Hyperplasia, Korean Journal of Urology, DOI:10.4111/kju.2010.51.8.557, diambil dari: www.kjurology.org.

Claus G, Roehrborn, John D, Connell MJ (2007). Benign Prostatic Hyperplasia: Etiology, Patophysiology, Epidemiology, and Natural History. In the: Walsh PC: Campbell’s Urology, 10th ed: chapter 86.

Connell MJ, Abrahams P (2009). Evaluation and Treatment of LUTS in Older Men. In the: Male urinary tract dysfunction evaluation and management. 4: 342-349.

Connell MJ (2005). Combination Theraphy Significantly Delays Progression of Benign Prostatic Hyperplasia. Diambil dari: www.nyp.org/news/hospital.

Feldman HA, Goldstein I, Krane RJ (2004). ‘Impotence and its Medical and Psycosocial Correlates: results of the Massachussetts Male Ageing Study’, J Urol, 151(1): 54-61.

Foster HE, Jacobs MB (2004). Transuretal Resection of the Prostate. In: Management of Benign Prostatic Hypertrophy. Northwestern University Feinberg School of Medicine, Chicago, IL. 10(11): 163-193.

Fouad RK, Vivien KT, Ronald S (2001). Male Sexual Function and its Disorders: Physiology, Patophysiology, Clinical Investigation and Treatment. Endocrine Reviews, 22: 342-348.

Goldstein I, Lue TF, Padma NH, Rosen RC, Steers WD, Wicker PA (1998). Oral Sildenafil in the Treatment of Erectile Dysfunction. Sildenafil Study Group. N Eng J Med, 338: 1397-1404.

Greenstein MA (2009). Enlarged Prostate. Medical Encyclopedia. Diambil dari: www.emedicine health.com/enlargedprostate/article.

Jaidane M, Arfa NB, Hmida W, Hidoussi A, Slama A, Sorba NB, Mosbah F (2013). Effect of Transurethral Resection of the Prostate in Erectile Function: A Prospective Comparative Study, International Journal of Impotence Research, 146-15.

Jeong HJ, Lee DH (2009). The Efficacy of Every Other Day Alpha – blocker Theraphy in Men with Benign Prostatic Hyperplasia. Korean J Urol, 46(4): 366-9.

Johanes BC, Araujo AB, Feldman HA (2000). Incidence of Erectile Dysfunction in Men 40 to 69 years old: Longitudinal Results from the Massachussetts Male Aging Study, The Journal of Urology, 163: 460-63.

Kirby R, Lepor H (2012). Evaluation and Nonsurgical Management of Benign Prostatic Hyperplasia. In the: Walsh PC, et al: Campbell’s Urology, 10th ed: Chapter 87.

Klein T, Eric A, Platz EA (2012). Epidemiology, Etiology, and Prevention of Benign Prostate Hyperplasia. In the Walsh PC, et al: Campbell’s Urology, 10th ed, WB Saunders – Elsevier, Philadelphia.

Klein T, Palisaar RJ, Holz A (2010). ‘The Impact TURP and Perprostatic Nerve Block on Erectile and Voiding Function: A Prospective Study’, The Journal of Urology, 184: 1456-52.

Lee C, Cockett A (2010). Regulation of Prostate Growth. In the: Chatelain C, Denis L, et al. Benign Prostate Hyperplasia, 5th: 81-99.

Mulhall J (2008). Erectile Dysfunction: Monitoring Response to Treatment in Clinical Practise – Recommendation an International Study Panel. J Sex Med, 4: 448-64.

Poulakis V, Ferakis N, Witzsch U, et al (2006). Erectile Dysfunction After Transurethral Prostatectomy for Lower Urinary Tract Symptoms: Results from A Center with Over 500 Patients. Asian J Androl; 8: 69-74.

Presti JC (2004). Neoplasms of the Prostate Gland. In the: Tanangho EA, Mc Aninch JW, editors. Smith’s General Urology. 16th ed New York : Lange Medical Books/Mc Graw – Hill: 367-385.

Roehrborn CG, Connell MJ (2002). Etiology, Patophysiology and Natural History of Benign Prostatic Hyperplasia. In the: Whals PC, Retik AB, Eds: Campbels Urology 9th. Philadelphia: WB Saunders; 1297-1330

Rhodes T, Marks LS, Dorey FJ, Shery ED, Rittenhouse H, Partin AW, Dekernion JB (2009). Serum Prostate Specific Antigen Level After Transurethral Resection of The Prostate: Longitudinal Characterization In Men With Benign Prostatic Hyperplasia. In: Journal of Urology, 156: 1035-1039.

Rosen RC, Cappeleri JC, Smith MD, Lipsky J (1999). Development and Evaluation of an Abridged, 5 item version of the International Index of Erectile Function (IIEF 5) as a Diagnostic Tool for Erectile Dysfunction. International Journal of Impotence Research. 11: 319-326.

Taher A (2004). Erectile Dysfunction After Transurethral Resection of the Prostate, Incidence and Risk Factors. World Journal Urology, 22: 457-460.

Wein AJ, Rovner ES (2001). Benign Prostatic Hyperplasia. In the: Hanno PM, Malkowicz SB, et al: Clinical Manual oof Urology, 3rd: 437-470.

Wespes E, Eardley I, Giuliano F, Hatzichristou D, Hatzimouratidis K, Moncada I, Salonia A, Vardi Y (2013). Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation. Arnhem (The Netherlands): European Association of Urology (EAU), 54: 326.

Zisman A, Leibovici, Kleinman J (2001). The Impact of TURP on Patient Well Being: A Prospective Study of Pain, Anxiety and Erectile Dysfunction. The Journal of Urology, 165: 445-454.

Downloads

Published

2017-10-17

Issue

Section

Articles